Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAD(P)H quinone dehydrogenase 1 (NQO1) is a cytosolic flavoprotein enzyme that plays a crucial role in cellular defense against oxidative stress and detoxification of quinones. It reduces quinones to hydroquinones, preventing the formation of reactive oxygen species. NQO1 also stabilizes the tumor suppressor p53. Altered expression or function has been linked with increased susceptibility to various cancers and potential involvement in neurodegenerative diseases. It is an important target for drug development, both for chemoprevention strategies and selective activation of anti-cancer agents.
Catalyzes the two-electron reduction of quinones to hydroquinones, preventing the formation of semiquinone radicals and reactive oxygen species. Activates certain cancer pro-drugs while protecting normal cells from oxidative damage.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NAD(P)H quinone dehydrogenase 1 (NQO1).